Xuefu Zhuyu Decoction Improves Blood-Brain Barrier Integrity in Acute Traumatic Brain Injury Rats via Regulating Adenosine.
10.1007/s11655-025-4200-7
- Author:
Yang WANG
1
;
Qiu-Ju YAN
1
;
En HU
1
;
Yao WU
1
;
Ruo-Qi DING
1
;
Quan CHEN
1
;
Meng-Han CHENG
1
;
Xi-Ya YANG
1
;
Tao TANG
1
;
Teng LI
2
Author Information
1. Institute of Integrative Medicine, Department of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China.
2. Institute of Integrative Medicine, Department of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, 410008, China. litengxiangya@csu.edu.cn.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Xuefu Zhuyu Decoction;
adenosine;
blood-brain barrier;
metabolomics;
traumatic brain injury
- MeSH:
Animals;
Drugs, Chinese Herbal/therapeutic use*;
Blood-Brain Barrier/metabolism*;
Brain Injuries, Traumatic/metabolism*;
Adenosine/metabolism*;
Male;
Rats, Sprague-Dawley;
Rats
- From:
Chinese journal of integrative medicine
2025;31(7):624-634
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To explore the neuroprotective effects of Xuefu Zhuyu Decoction (XFZYD) based on in vivo and metabolomics experiments.
METHODS:Traumatic brain injury (TBI) was induced via a controlled cortical impact (CCI) method. Thirty rats were randomly divided into 3 groups (10 for each): sham, CCI and XFZYD groups (9 g/kg). The administration was performed by intragastric administration for 3 days. Neurological functions tests, histology staining, coagulation and haemorheology assays, and Western blot were examined. Untargeted metabolomics was employed to identify metabolites. The key metabolite was validated by enzyme-linked immunosorbent assay and immunofluorescence.
RESULTS:XFZYD significantly alleviated neurological dysfunction in CCI model rats (P<0.01) but had no impact on coagulation function. As evidenced by Evans blue and IgG staining, XFZYD effectively prevented blood-brain barrier (BBB) disruption (P<0.05, P<0.01). Moreover, XFZYD not only increased the expression of collagen IV, occludin and zona occludens 1 but also decreased matrix metalloproteinase-9 (MMP-9) and cyclooxygenase-2 (COX-2), which protected BBB integrity (all P<0.05). Nine potential metabolites were identified, and all of them were reversed by XFZYD. Adenosine was the most significantly altered metabolite related to BBB repair. XFZYD significantly reduced the level of equilibrative nucleoside transporter 2 (ENT2) and increased adenosine (P<0.01), which may improve BBB integrity.
CONCLUSIONS:XFZYD ameliorates BBB disruption after TBI by decreasing the levels of MMP-9 and COX-2. Through further exploration via metabolomics, we found that XFZYD may exert a protective effect on BBB by regulating adenosine metabolism via ENT2.
